✨ Free AI Report
SIGA Technologies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research SIGA Technologies, Inc.
Company Research

SIGA Technologies, Inc.: Business Overview, Financials & Competitive Analysis

SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security with a focus on treating serious infectious diseases. Its flagship product TPOXX (tecovirimat) is an FDA-approved antivira...

Analyst-debate audio for SIGA Technologies, Inc.

AskCyborg analysts argue the bull and bear cases for SIGA Technologies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Specialized biotech with de-risked revenue from government contracts and significant upside from pipeline approvals in PEP...

Read the full analyst-debate transcript →
Industry Pharmaceutical/Biotech - Health Security & Infectious Diseases
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest SIGA Technologies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

SIGA Technologies, Inc. Overview

Pro stress-test →

SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security with a focus on treating serious infectious diseases. Its flagship product TPOXX (tecovirimat) is an FDA-approved antiviral for smallpox treatment and is authorized internationally for smallpox, monkeypox, cowpox, and vaccinia complications, with significant revenue derived from U.S. government contracts.

Strategic Profile

Pro stress-test →

SIGA maintains a strong strategic position through four key pillars: continued partnership with the U.S. government (primary revenue source), advancing regulatory approvals for new TPOXX indications and formulations, expanding international market access, and developing complementary therapeutic areas. The company has strong financial flexibility with $182 million in cash, no debt, and is pursuing post-exposure prophylaxis (PEP) and pediatric formulations to drive future growth.

Competitive Landscape

Pro stress-test →

SIGA operates in a specialized market focused on biodefense and orthopoxvirus treatments. The company faces limited direct competition for smallpox treatments, though monkeypox/mpox treatment space has become more competitive. Key competitive advantages include TPOXX's first-mover status, FDA/international approvals across multiple indications, and established U.S. government relationship. Potential future competitors include companies developing alternative antivirals or monoclonal antibodies for orthopoxviruses.

Industry Context

SIGA Technologies, Inc. operates in Pharmaceutical/Biotech - Health Security & Infectious Diseases.

Key facts

Founded: 1995 · Headquarters: New York, US · Employees: 46 · Revenue: N/A · Market cap: $483M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on SIGA Technologies, Inc..

  • U.S. government contracts are primary revenue driver with $79 million in Q2 2025 product deliveries and $27 million in development funding, demonstrating strong biosecurity demand
  • FDA submission targeted for first half of 2026 for TPOXX PEP (post-exposure prophylaxis) indication represents clear catalyst for new revenue stream expansion
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Q2 2025Strong product deliveries of $79 million and development funding of $27 million from U.S. government contracts
  • H2 2025Pediatric TPOXX IND submission planned with clinical trials expected to commence thereafter
  • +2 moreTrack every material event for SIGA Technologies, Inc. as it happens. Explore monitoring →
Get alerted when SIGA Technologies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Monoclonal antibody therapiesEmerging alternatives for orthopoxvirus treatment→Tecovirimat generics/biosimilarsPost-patent competition risk→

Compare SIGA Technologies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

SIGA Technologies, Inc. operates in Pharmaceutical/Biotech - Health Security & Infectious Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical/Biotech - Health Security & Infectious Diseases research →
NEW · MCP server

Ask your AI assistant about SIGA Technologies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare SIGA Technologies, Inc. and its top competitor on Cyborg Score”
“What did SIGA Technologies, Inc. do this quarter?”
“Is SIGA Technologies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does SIGA Technologies, Inc. do?+
SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security with a focus on treating serious infectious diseases. Its flagship product TPOXX (tecovirimat) is an FDA-approved antivira...
What is SIGA Technologies, Inc.'s Cyborg Score?+
SIGA Technologies, Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are SIGA Technologies, Inc.'s main competitors?+
Named competitors include Monoclonal antibody therapies, Tecovirimat generics/biosimilars. The full competitive landscape is in the AskCyborg report.
How can I get the full SIGA Technologies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the SIGA Technologies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track SIGA Technologies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Elanco Animal Health Incorporated7Nanexa AB4Aquestive Therapeutics, Inc.3Boundless Bio, Inc.